Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 26 09:30AM ET
0.9800
Dollar change
0.0000
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.37 Insider Own21.92% Shs Outstand4.44M Perf Week2.08%
Market Cap4.36M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.48M Perf Month-37.18%
Income-6.01M PEG- EPS next Q- Inst Own8.04% Short Float0.42% Perf Quarter-43.74%
Sales0.00M P/S- EPS this Y- Inst Trans-1.72% Short Ratio0.96 Perf Half Y22.50%
Book/sh0.48 P/B2.04 EPS next Y- ROA-117.26% Short Interest0.01M Perf Year-50.75%
Cash/sh0.54 P/C1.80 EPS next 5Y- ROE-140.56% 52W Range0.68 - 2.22 Perf YTD-1.01%
Dividend Est.- P/FCF- EPS past 5Y-2.91% ROI-281.68% 52W High-55.86% Beta-
Dividend TTM- Quick Ratio5.53 Sales past 5Y0.00% Gross Margin- 52W Low44.18% ATR (14)0.13
Dividend Ex-Date- Current Ratio5.53 EPS Y/Y TTM-103.80% Oper. Margin0.00% RSI (14)40.77 Volatility12.56% 11.07%
Employees3 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price16.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-133.79% Payout- Rel Volume0.38 Prev Close0.98
Sales Surprise- EPS Surprise37.50% Sales Q/Q- EarningsApr 01 AMC Avg Volume15.29K Price0.98
SMA20-11.50% SMA50-24.08% SMA200-16.14% Trades Volume1,055 Change0.00%
Jun-25-24 06:53AM
May-22-24 08:12AM
May-01-24 08:38AM
Apr-17-24 08:42AM
Apr-01-24 09:53PM
04:20PM Loading…
04:20PM
Mar-27-24 08:42AM
Mar-25-24 05:00PM
Mar-21-24 08:41AM
Feb-13-24 08:30AM
Dec-12-23 07:30AM
Oct-13-23 09:00AM
Sep-26-23 08:18AM
Mar-22-23 12:55PM
Apr-26-22 08:15AM
09:58AM Loading…
Nov-16-21 09:58AM
Aug-30-21 09:15AM
Aug-17-21 07:45AM
Jul-23-21 04:21PM
Jul-08-21 11:20AM
Jul-06-21 06:17AM
Jun-23-21 09:35AM
Jun-16-21 09:15AM
Apr-29-21 03:06PM
Apr-26-21 08:58PM
Dec-16-20 09:15AM
Sep-08-20 12:10PM
Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arrow Alexander K.Chief Financial OfficerOct 12 '23Buy0.818,0006,48045,815Oct 13 12:48 PM